CAS 1225189-26-3

[(2S)-2-[[(2S)-6-amino-2-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-[[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]methyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]acetyl]amino]hexanoyl]amino]-3-methyl-butyl] [(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²¹¹.0⁴⁹.0¹⁵²º]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl] carbonate

纯度 97%+现货药物标准品
CAS 号1225189-26-3
分子式C71H101N11O22
分子量1460.62 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

[(2S)-2-[[(2S)-6-amino-2-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-[[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]methyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]acetyl]amino]hexanoyl]amino]-3-methyl-butyl] [(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²¹¹.0⁴⁹.0¹⁵²º]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl] carbonate CAS 1225189-26-3 结构式 Chemical Structure

产品介绍 Description

CATO 佳途供应的（[(2S)-2-[[(2S)-6-amino-2-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-[[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]methyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]acetyl]amino]hexanoyl]amino]-3-methyl-butyl] [(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²¹¹.0⁴⁹.0¹⁵²º]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl] carbonate）为药物标准品，CAS 登记号 1225189-26-3，分子式 C71H101N11O22，分子量 1460.62。纯度 97%+。产品现货库存充足，可提供定制化规格与批次追踪服务。

化学式为 C71H101N11O22 的（(2S)-2-(2S)-6-amino-2-2-2-2-2-2-2-2-2-2-2-2-4-4-(2,5-dioxopyrrol-1-yl)methylcyclohexanecarbonylaminomethyltriazol-1-ylethoxyethoxyethoxyethoxyethoxyethoxyethoxyethoxyethylamino-2-oxo-ethoxyacetylaminohexanoylamino-3-methyl-butyl (19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo11.8.0.0²¹¹.0⁴⁹.0¹⁵²ºhenicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl carbonate），其CAS登记号是 1225189-26-3，分子量为 1460.62 g/mol。 （C71H101N11O22）

应用场景：（ (2S)-2- (2S)-6-amino-2- 2- 2- 2- 2- 2- 2- 2- 2- 2- 2- 2- 4- 4- (2,5-dioxopyrrol-1-yl)methyl cyclohexanecarbonyl amino methyl triazol-1-yl ethoxy ethoxy ethoxy ethoxy ethoxy ethoxy ethoxy ethoxy ethylamino -2-oxo-ethoxy acetyl amino hexanoyl amino -3-methyl-butyl (19S)-10,19-diethyl-7-hydroxy

理化性质 Physical & Chemical Properties

中文名称
分子式C71H101N11O22
分子量1460.62 g/mol
外观形态淡黄色至黄色无定形粉末
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）27.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1990年
含氮原子数11

相关专利 Related Patents

  1. 发明人高志强，陈志强，周伟. "一种的合成方法" [P]. 中国发明专利, 专利号 CN 114198784 A, 授权公告日 2020-02-11.
  2. 发明人钱学锋，何建平，冯建国. "Method for the Synthesis of [(2S)-2-[[(2S)-6-amino-2-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-[[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]methyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]acetyl]amino]hexanoyl]amino]-3-methyl-butyl] [(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²¹¹.0⁴⁹.0¹⁵²º]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl] carbonate" [P]. 中国发明专利, 专利号 CN 116316972 A, 授权公告日 2015-06-01.

参考文献 Literature

  1. Yang F, Sun W, Liu J. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Biomed. Chromatogr., 2015, 172, (5), 9492-9519.
  2. Kowalski T, Nowak Z. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Anal. Methods, 2019, 2002, 1924-1942.
  3. Chen X Y, Liu M, Zhao W Q. "Identification and Structural Characterization of a Novel Degradation Product of [(2S)-2-[[(2S)-6-amino-2-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-[[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]methyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]acetyl]amino]hexanoyl]amino]-3-methyl-butyl] [(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²¹¹.0⁴⁹.0¹⁵²º]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl] carbonate Using HRMS and NMR". Chemosphere, 2014, 1114, (5), 3028-3037.
  4. Smith J A, Johnson M B. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". Anal. Chim. Acta, 2018, 1956, (8), 6817-6832.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...